Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113303405> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2113303405 endingPage "8718" @default.
- W2113303405 startingPage "8715" @default.
- W2113303405 abstract "Background: ABVD (doxorubicin, bleomycin, vinblastine (Vb) and dacarbazine) is the standard regimen in Hodgkin's lymphoma (HL).Vincristine (O) is a mitotic spindle agent like Vb. We aimed to evaluate the efficacy and safety of O as a part of ABOD in HL. Materials and Methods: Patients who had ABOD were enrolled. Stage I-II HL were evaluated for unfavorable risk factors according to NCCN. National Cancer Institute Common Toxicity Criteria was used for toxicity. Results: Seventy-nine HL patients in our center between 2003 and 2007 were evaluated retrospectively. Median follow-up was 54 months. Most of the patients were male in their third decade. Median ABOD cycles were 6 (2-8). Primary refractory disease rate was 17.7% whereas it was 5.1% for early relapse and 5.1% for late relapse disease. Response rates were as 82.3% for complete response, 11.4% for partial response, 5.1% for stable disease and 1.3% for progressive disease. Half of relapsed patients had autologous stem cell transplantation. Estimated 5-year failure-free survival was 71% and significantly longer in early stage patients without risk factors, bulky disease or radiotherapy (RT) (p=0.05, p<0.0001, p=0.02; respectively). Estimated 5-year overall survival was 74% and significantly longer in those who had no RT (p=0.001). Dose modification rate was 5.1% and chemotherapy delay rate was 19%. There were no toxicity-related deaths. Conclusions: ABOD seems to be effective with managable toxicity in HL, even in those with poor prognostic factors." @default.
- W2113303405 created "2016-06-24" @default.
- W2113303405 creator A5002599142 @default.
- W2113303405 creator A5018830053 @default.
- W2113303405 creator A5027860268 @default.
- W2113303405 creator A5046987799 @default.
- W2113303405 creator A5052748672 @default.
- W2113303405 creator A5054275694 @default.
- W2113303405 creator A5069536993 @default.
- W2113303405 creator A5080983521 @default.
- W2113303405 creator A5089097501 @default.
- W2113303405 date "2014-11-06" @default.
- W2113303405 modified "2023-10-16" @default.
- W2113303405 title "Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin's Lymphoma: a Single Institute Experience" @default.
- W2113303405 cites W1865367030 @default.
- W2113303405 cites W2014698797 @default.
- W2113303405 cites W2040548891 @default.
- W2113303405 cites W2099126154 @default.
- W2113303405 cites W2115623689 @default.
- W2113303405 cites W2118169390 @default.
- W2113303405 cites W2133260927 @default.
- W2113303405 cites W2156613346 @default.
- W2113303405 cites W2162848902 @default.
- W2113303405 cites W2165308914 @default.
- W2113303405 doi "https://doi.org/10.7314/apjcp.2014.15.20.8715" @default.
- W2113303405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25374196" @default.
- W2113303405 hasPublicationYear "2014" @default.
- W2113303405 type Work @default.
- W2113303405 sameAs 2113303405 @default.
- W2113303405 citedByCount "3" @default.
- W2113303405 countsByYear W21133034052021 @default.
- W2113303405 countsByYear W21133034052022 @default.
- W2113303405 crossrefType "journal-article" @default.
- W2113303405 hasAuthorship W2113303405A5002599142 @default.
- W2113303405 hasAuthorship W2113303405A5018830053 @default.
- W2113303405 hasAuthorship W2113303405A5027860268 @default.
- W2113303405 hasAuthorship W2113303405A5046987799 @default.
- W2113303405 hasAuthorship W2113303405A5052748672 @default.
- W2113303405 hasAuthorship W2113303405A5054275694 @default.
- W2113303405 hasAuthorship W2113303405A5069536993 @default.
- W2113303405 hasAuthorship W2113303405A5080983521 @default.
- W2113303405 hasAuthorship W2113303405A5089097501 @default.
- W2113303405 hasBestOaLocation W21133034051 @default.
- W2113303405 hasConcept C126322002 @default.
- W2113303405 hasConcept C141071460 @default.
- W2113303405 hasConcept C143998085 @default.
- W2113303405 hasConcept C2776232574 @default.
- W2113303405 hasConcept C2776305933 @default.
- W2113303405 hasConcept C2776694085 @default.
- W2113303405 hasConcept C2776755627 @default.
- W2113303405 hasConcept C2777132456 @default.
- W2113303405 hasConcept C2778822529 @default.
- W2113303405 hasConcept C2779429289 @default.
- W2113303405 hasConcept C2780964509 @default.
- W2113303405 hasConcept C2781413609 @default.
- W2113303405 hasConcept C29730261 @default.
- W2113303405 hasConcept C71924100 @default.
- W2113303405 hasConcept C90924648 @default.
- W2113303405 hasConceptScore W2113303405C126322002 @default.
- W2113303405 hasConceptScore W2113303405C141071460 @default.
- W2113303405 hasConceptScore W2113303405C143998085 @default.
- W2113303405 hasConceptScore W2113303405C2776232574 @default.
- W2113303405 hasConceptScore W2113303405C2776305933 @default.
- W2113303405 hasConceptScore W2113303405C2776694085 @default.
- W2113303405 hasConceptScore W2113303405C2776755627 @default.
- W2113303405 hasConceptScore W2113303405C2777132456 @default.
- W2113303405 hasConceptScore W2113303405C2778822529 @default.
- W2113303405 hasConceptScore W2113303405C2779429289 @default.
- W2113303405 hasConceptScore W2113303405C2780964509 @default.
- W2113303405 hasConceptScore W2113303405C2781413609 @default.
- W2113303405 hasConceptScore W2113303405C29730261 @default.
- W2113303405 hasConceptScore W2113303405C71924100 @default.
- W2113303405 hasConceptScore W2113303405C90924648 @default.
- W2113303405 hasIssue "20" @default.
- W2113303405 hasLocation W21133034051 @default.
- W2113303405 hasLocation W21133034052 @default.
- W2113303405 hasOpenAccess W2113303405 @default.
- W2113303405 hasPrimaryLocation W21133034051 @default.
- W2113303405 hasRelatedWork W2008127541 @default.
- W2113303405 hasRelatedWork W2019922408 @default.
- W2113303405 hasRelatedWork W2058793701 @default.
- W2113303405 hasRelatedWork W2068623214 @default.
- W2113303405 hasRelatedWork W2077424156 @default.
- W2113303405 hasRelatedWork W2118169390 @default.
- W2113303405 hasRelatedWork W2136126001 @default.
- W2113303405 hasRelatedWork W2339248445 @default.
- W2113303405 hasRelatedWork W2417943760 @default.
- W2113303405 hasRelatedWork W2426888873 @default.
- W2113303405 hasVolume "15" @default.
- W2113303405 isParatext "false" @default.
- W2113303405 isRetracted "false" @default.
- W2113303405 magId "2113303405" @default.
- W2113303405 workType "article" @default.